How to use Keytruda Vial

Read the Medication Guide provided by your pharmacist before you start receiving pembrolizumab and each time you get a treatment. If you have any questions, ask your doctor or pharmacist.

This medication is given by a health care professional. It is injected slowly into a vein over 30 minutes. It is given as directed by your doctor, usually once every 3 weeks or once every 6 weeks. The dosage is based on your medical condition and response to treatment. Children's dose is also based on weight.

Symptoms of a severe infusion reaction that may occur during pembrolizumab treatment include fever, chills, shaking, flushing, trouble breathing, dizziness, or feeling faint. Tell your healthcare provider right away if you have any of these symptoms during your treatment.

Use this medication regularly to get the most benefit from it. To help you remember, mark the days on the calendar when you need to receive the medication.

Side Effects

Tiredness, swelling ankles/feet/hands, itchy skin, nausea, vomiting, abdominal pain, or trouble sleeping may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

People using this medication may have serious side effects. Some of these effects may occur even after stopping treatment. However, you have been prescribed this drug because your doctor has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk.

Tell your doctor right away if you have any serious side effects, including: headache that is unusual or doesn't go away, new/worsening cough, shortness of breath, diarrhea with blood/mucus, symptoms of liver disease (such as nausea/vomiting that doesn't stop, loss of appetite, stomach/abdominal pain, yellowing eyes/skin, dark urine), signs of kidney problems (such as change in the amount of urine, pink/bloody urine), dizziness/fainting, vision changes, deepening of the voice, eye redness/pain, sensitivity to light, numbness/tingling of the arms/legs, joint stiffness/pain, muscle weakness/tenderness/pain, signs of infection (such as sore throat that doesn't go away, fever, chills, burning/painful/frequent/urgent urination), easy bruising/bleeding.

Pembrolizumab may cause hormone gland problems (such as thyroid, pituitary, adrenal, pancreas). Your body could make too much or too little hormone. Tell your doctor right away if you have any symptoms such as: cold or heat intolerance, unexplained weight loss/gain, mental/mood changes, slow/fast/pounding/irregular heartbeat, unusual tiredness, constipation.

This medication may rarely make your blood sugar rise, which can cause or worsen diabetes. Tell your doctor right away if you have symptoms of high blood sugar such as increased thirst/urination. If you already have diabetes, check your blood sugar regularly as directed and share the results with your doctor. Your doctor may need to adjust your diabetes medication, exercise program, or diet.

Get medical help right away if you have any very serious side effects, including: chest pain, seizure.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before using pembrolizumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: organ transplant.

People who receive a donor stem cell transplant after treatment with pembrolizumab may have very serious (possibly fatal) complications. Ask your doctor for more details.

This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using pembrolizumab. Pembrolizumab may harm an unborn baby. Ask about reliable forms of birth control while using this medication and for 4 months after the last dose. If you become pregnant, talk to your doctor right away about the risks and benefits of this medication.

It is unknown if this drug passes into breast milk. Because of the possible risk to the infant, breastfeeding is not recommended while using this drug and for 4 months after the last dose. Consult your doctor before breastfeeding.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Does Keytruda Vial interact with other drugs you are taking?
Enter your medication into the WebMD interaction checker

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

Notes Notes

Lab and/or medical tests (such as liver/kidney/thyroid function, blood sugar, complete blood count) should be done before and during treatment with this medication. Keep all medical and lab appointments. Consult your doctor for more details.

Missed Dose Missed Dose

It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule.

Storage Storage

Not applicable. This medication is given in a hospital or clinic and will not be stored at home.

Images

Keytruda 25 mg/mL intravenous solution

Keytruda 25 mg/mL intravenous solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

Keytruda 25 mg/mL intravenous solution

Keytruda 25 mg/mL intravenous solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

Look up another drug

Find other drugs that treat your condition

Select a condition
malignant melanoma, a type of skin cancer
PD-L1 positive non-small cell lung cancer
squamous cell carcinoma of head and neck
a type of cancer of the lymph nodes called Hodgkin's lymphoma
cancer or malignancy
EGFR negative, ALK negative, non-small cell lung cancer
cancer of the urinary tract lining
microsatellite instability-high solid cancer
microsatellite instability-high colorectal cancer
HER2-positive gastric adenocarcinoma
early-stage triple-negative breast cancer
carcinoma cancer of the cervix
primary mediastinal large B-cell lymphoma
PD-L1 positive cervical cancer
non-small cell lung cancer
liver cell carcinoma
a type of skin cancer called Merkel cell carcinoma
added therapy to improve treatment of melanoma
renal cell carcinoma
PD-L1 expressing triple-negative breast cancer
PD-L1 positive squamous cell carcinoma of the esophagus
cancer in the lining of the uterus
non-muscle invasive bladder cancer with carcinoma in situ
solid malignant tumor with high mutation burden
cancer of the squamous cells in the skin
cancer of the esophagus
cancer of gallbladder or bile ducts
HER2-negative gastric or gastroesophageal junction adenocarcinoma

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.